Kyowa Hakko Europe is to increase prices across its range of
L-amino acids by ten per cent as of April 1, in an effort to stave
off margin deterioration and ensure long-term availability of the
ingredients.
Lonza has boosted its capacity to produce peptides through liquid
phase technology with the €120 million acquisition of UCB's
Bioproducts manufacturing division.